Literature DB >> 33118129

Ustekinumab is effective against small bowel lesions in Crohn's disease: two case reports.

Kentaro Murate1, Masanao Nakamura2, Takeshi Yamamura1, Keiko Maeda3, Tsunaki Sawada3, Yasuyuki Mizutani1, Eri Ishikawa1, Naomi Kakushima1, Kazuhiro Furukawa1, Eizaburo Ohno1, Takashi Honda1, Hiroki Kawashima3, Masatoshi Ishigami1, Mitsuhiro Fujishiro1.   

Abstract

We encountered two patients with Crohn's disease (CD) for whom induction of ustekinumab was effective for the management of small intestinal lesions with stenosis. The first symptomatic CD case was a 40-year-old female with longitudinal ulcers in the small bowel found at double-balloon endoscopy. She was in a biologic-naïve condition. Her symptoms improved immediately after ustekinumab induction. We confirmed the condition of intestinal mucosa by double-balloon endoscopy. Deep ulcers remained open at 24 weeks and were scarred at 72 weeks. The second case was a 50-year-old male who failed to respond to treatment with anti-TNFα agents. The lumen was narrow caused by circumferential ulcer, and an endoscope could not pass the site before induction. The circumferential ulcer had been healed by ustekinumab induction, and an endoscope passed through at 72 weeks. These two cases support the therapeutic efficacy of ustekinumab in alleviating small bowel lesions in CD patients.

Entities:  

Keywords:  Crohn’s disease; Fibrosis; Small bowel; Stenosis; Ustekinumab

Mesh:

Substances:

Year:  2020        PMID: 33118129     DOI: 10.1007/s12328-020-01242-0

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  2 in total

Review 1.  Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

Authors:  Javier P Gisbert; Julián Panés
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

2.  Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study.

Authors:  Eduard Louis; Jacques Boverie; Olivier Dewit; Filip Baert; Martine De Vos; Geert D'Haens
Journal:  Acta Gastroenterol Belg       Date:  2007 Jan-Mar       Impact factor: 1.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.